Document:

Document

Exhibit 10.1

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential

VIA DocuSign

[***]
[***]

            Re:      Discretionary Equity Award and Bonus

Dear [           ]:

As was discussed [***], we appreciate your valuable contributions to Oyster Point Pharma, Inc. (the “Company”) and it is the desire of the Company that you continue your employment.  As an incentive for this continued employment with the Company, and assuming you sign below, you are eligible to receive the following:

1.A discretionary grant of [           ] Performance Stock Units of the Company’s Common Stock (the “Discretionary Equity Award”), which was approved by the unanimous written consent of the Company’s Board of Directors (the “Board”) on July 6, 2022, and as determined in accordance with the Company’s 2019 Equity Incentive Plan (the “Plan”), and further subject to the following terms:

a.You must remain employed and in good standing with the Company as of the dates of the following vesting schedule: 

a.One-half (1/2) of the Discretionary Equity Award will vest on July 6, 2023; and
b.One-half (1/2) of the Discretionary Equity Award will vest at such time, if any, during the period that begins on July 6, 2023, and ending on July 6, 2024 (the “VWAP Vesting Period”), as the thirty (30)-day volume-weighted average stock price (the “VWAP”) reaches $6.00 (the “VWAP Based Vesting Requirement”). In order to satisfy the VWAP Based Vesting Requirement, the applicable thirty (30) consecutive day period must occur entirely during the VWAP Vesting Period and the VWAP will be measuring during any thirty (30) consecutive trading days during such period.

i.The Discretionary Equity Award will not be considered fully vested until July 6, 2024 (the “Discretionary Equity Date”).  Therefore, if you voluntarily separate from the Company before the Discretionary Equity Date without Good Reason, or if you are terminated for Cause (and other than as a result of death or Disability), you will not be eligible to retain any unvested portion(s) of the Discretionary Equity Award.  The Discretionary Equity Award is subject to the terms and conditions of the Plan, as in effect at the time and as updated as necessary by the Board in its sole discretion. The Discretionary Equity Award will also be subject to the terms and conditions of new forms of PSU award documentation to reflect the Performance Stock Units terms as approved by the Board. 

Exhibit 10.1

i.Your Discretionary Equity Award (or unvested portion thereof) will be eligible for accelerated vesting upon a qualifying termination in connection with a Change in Control as provided in the Oyster Point Pharma, Inc. Change in Control and Severance Agreement applicable to you.  

a.A one-time discretionary advance payment in the amount of $[           ], which the Company expects to provide on July 15, 2022 (the “Discretionary Bonus”), less applicable taxes and withholdings, subject to the following terms:

i.You must remain continuously employed by the Company and in good standing with the Company as of December 31, 2022. 

i.The Discretionary Bonus will not be considered earned until December 31, 2022 (the “Discretionary Date”).  Therefore, if you voluntarily separate from the Company before the Discretionary Date without Good Reason, or if you are terminated for Cause (and other than as a result of death or Disability), then you (i) will not be considered to have earned the Discretionary Bonus,  and (ii) must repay the net after-tax amount of the Discretionary Bonus in full within [           ] calendar days after your final date of employment with the Company.  You also agree that in the event you fail to repay any portion of the Discretionary Bonus, the Company will be entitled to recover its reasonable legal fees and costs incurred through seeking to recover any amounts owed.  

As used in this letter, the terms “Cause”, “Change in Control”, “Disability, and “Good Reason” will have the meanings set forth in the Oyster Point Pharma, Inc. Change in Control and Severance Agreement applicable to you.  

All other terms and conditions of your employment remain unchanged, including your “at-will” employment status. You and/or the Company remain free to terminate your employment at any time for any reason.

We thank you for your continued contributions to the Company.  If you agree with the above terms, please sign and date where indicated below and return it to Matt Taylor, Director, HR Operations at [***] or Oyster Point Pharma, Inc., 202 Carnegie Center, Suite 109, Princeton, NJ 08540.  Of course, please let me know if you have any questions.  

Oyster Point Pharma, Inc. 

                        By:      /s/ Dave Benadon                
                                                                                                Dave Benadon
Chief Human Resources Officer

Agreed to and Accepted by: 

Name: [           ]
Dated: [           ]Exhibit 10.1
​
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT
​
THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of May 13, 2022, is entered into by and among CENTURY THERAPEUTICS, INC., a Delaware corporation and successor to Century Therapeutics, LLC, and each of its Subsidiaries (hereinafter collectively referred to as “Borrower”), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (as defined below) (collectively, referred to as the “Lenders”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for the Lenders (in such capacity, “Agent”).
​
Borrower, Lenders and Agent are parties to that certain Loan and Security Agreement, dated as of September 14, 2020 (the “Existing Loan Agreement”; and the Existing Loan Agreement, as amended by this Amendment and as further amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”). Borrower has requested that the Lenders agree to certain amendments to the Loan and Security Agreement. Lenders have agreed to such request, subject to the terms and conditions hereof.
​
Accordingly, the parties hereto agree as follows:
​
SECTION 1    Definitions; Interpretation.
​
(a)Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement.
​
(b)Rules of Construction. The rules of construction that appear in Section 1.3 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference.
​
SECTION 2    Amendments to the Loan Agreement.
​
(a)Upon satisfaction of the conditions set forth in Section 3 hereof, the Existing Loan Agreement is hereby amended as follows:
​
		(i)
	New Definitions. The following definition is added to Section 1.1 in its proper alphabetical

order:
​
“Monthly Reporting Waiver Condition” means, for any calendar month, Borrower maintained in Deposit Accounts subject to an Account Control Agreement in favor of Agent, at all times during such month, minimum unrestricted Cash of at least Twenty-Five Million Dollars.
​
		(ii)
	Amended Definition. The following definition in Section 1.1 is amended and restated as

follows:
​
“Amortization Date” means May 1, 2023.
​
		(iii)
	Section 7.1. Section 7.1(a) is hereby amended and restated as follows:

​
(a)as soon as practicable (and in any event within thirty (30) days) after the end of each month, unless the Monthly Reporting Waiver Condition has been satisfied for such month), unaudited interim and year-to-date financial statements as of the end of such month (prepared on a consolidated basis), including balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that could reasonably be expected to have a Material Adverse Effect, all certified by Borrower’s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year-end adjustments, and (iii)
​
​

​
they do not contain certain non-cash items that are customarily included in quarterly and annual financial statements;
​
		(iv)
	Section 7.1. Section 7.1(d) is hereby amended and restated as follows:

​
(d)   (i) as soon as practicable after the end of each month (and in any event within    thirty (30) days after the end of each such month) and (ii) together with the financial statements delivered as required by Sections 7.1(b) through (c), a Compliance Certificate in the form of Exhibit E;
​
		(v)
	Exhibit E is replaced in its entirety with the Exhibit E attached hereto.

​
(b)References Within Existing Loan Agreement. Each reference in the Existing Loan Agreement to “this Agreement” and the words “hereof,” “herein,” “hereunder,” or words of like import, shall mean and be a reference to the Existing Loan Agreement as amended by this Amendment.
​
SECTION 3    Conditions of Effectiveness. The effectiveness of Section 2 of this Amendment shall be subject to the satisfaction of each of the following conditions precedent:
​
(a)Borrower shall have paid (i) all invoiced costs and expenses then due in accordance with Section 5(e), and (ii) all other fees, costs and expenses, if any, due and payable as of the date hereof under the Loan Agreement.
​
		(b)
	Agent shall have received this Amendment, executed by Agent, Lenders and Borrower.

​
(c)On the date hereof, after giving effect to the amendment of the Existing Loan Agreement contemplated hereby, there exist no Events of Default or events that with the passage of time would result in an Event of Default.
​
SECTION 4    Representations and Warranties.   To induce Agent and Lenders to enter into this Amendment,  each Borrower hereby confirms, as of the date hereof, that (a) the representations and warranties made by it in Section 5 of the Loan Agreement and in the other Loan Documents are true and correct in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof provided, further, that to the extent such representations and warranties by their terms expressly relate only to a prior date such representations and warranties shall be true and correct as of such prior date; (b) there has not been and there does not exist a Material Adverse Effect; (c) that the information included in the Perfection Certificate delivered to Agent on the Closing Date remains true and correct; (d) Agent has and shall continue to have valid, enforceable and perfected first-priority liens, subject only to Permitted Liens, on and security interests in the Collateral and all other collateral heretofore granted by Borrower to Agent, pursuant to the Loan Documents or otherwise granted to or held by Agent; (e) the agreements and obligations of Borrower contained in the Loan Documents and in this Amendment constitute the legal, valid and binding obligations of Borrower, enforceable against Borrower in accordance with their respective terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditors’ rights or by the application of general principles of equity; (f) the execution, delivery and performance of this Amendment by Borrower will not violate any law, rule, regulation, order, contractual obligation or organizational document of Borrower and will not result in, or require, the creation or imposition of any lien, claim or encumbrance of any kind on any of its properties or revenues; and (g) no Event of Default has occurred and is continuing.
​
SECTION 5    Miscellaneous.
​
		(a)
	Loan Documents Otherwise Not Affected; Reaffirmation; No Novation.

​
(i)Except as expressly amended pursuant hereto or referenced herein, the Existing Loan Agreement and the other Loan Documents shall remain unchanged and in full force and effect and are hereby ratified and confirmed in all respects. Lenders’ and Agent’s execution and delivery of, or acceptance of, this Amendment
​
​
​

2

​
shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future.
​
(ii)Borrower hereby expressly (1) reaffirms, ratifies and confirms its Secured Obligations under the Existing Loan Agreement and the other Loan Documents, (2) reaffirms, ratifies and confirms the grant of security under Section 3.1 of the Existing Loan Agreement, (3) reaffirms that such grant of security in the Collateral secures all Secured Obligations under the Existing Loan Agreement, including without limitation any Term Loans funded on or after the date hereof, as of the date hereof, and with effect from (and including) the date hereof, such grant of security in the Collateral: (x) remains in full force and effect notwithstanding the amendments expressly referenced herein; and (y) secures all Secured Obligations under the Existing Loan Agreement, as amended by this Amendment, and the other Loan Documents, and (4) agrees that the Existing Loan Agreement and each other Loan Document shall remain in full force and effect following any action contemplated in connection herewith.
​
(iii)This Amendment is not a novation and the terms and conditions of this Amendment shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents. Nothing in this Amendment is intended, or shall be construed, to constitute an accord and satisfaction of Borrower’s Secured Obligations under or in connection with the Existing Loan Agreement and any other Loan Document or to modify, affect or impair the perfection or continuity of Agent’s security interest in, (on behalf of itself and Lenders) security titles to or other liens on any Collateral for the Secured Obligations.
​
(b)Conditions. For purposes of determining compliance with the conditions specified in Section 3, Lenders that have signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to Lenders unless Agent shall have received notice from Lenders prior to the date hereof specifying its objection thereto.
​
(c)Release. In consideration of the agreements of Agent and Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Borrower, on behalf of itself and its successors, assigns, and other legal representatives, hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and Lenders, and its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Lenders and all such other persons being hereinafter referred to collectively as the “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment for or on account of, or in relation to, or in any way in connection with the Loan Agreement, or any of the other Loan Documents or the transactions thereunder or related thereto. Each Borrower waives the provisions of California Civil Code section 1542, which states:
​
A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.
​
Each Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release. Each Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above. The provisions of this section shall survive payment in full of the Secured Obligations, full performance of all the terms of this Amendment and the other Loan Documents.
​
​

3

​
(d)No Reliance. Borrower hereby acknowledges and confirms to Agent and Lenders that Borrower is executing this Amendment on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any other Person.
​
(e)Costs and Expenses. Borrower agrees to pay to Agent on the date hereof the out-of-pocket costs and expenses of Agent and Lenders party hereto, and the fees and disbursements of counsel to Agent and Lenders party hereto in connection with the negotiation, preparation, execution and delivery of this Amendment and any other documents to be delivered in connection herewith on the date hereof.
​
(f)Binding Effect. This Amendment binds and is for the benefit of the successors and permitted assigns of each party.
​
(g)Governing Law. This Amendment and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.
​
(h)Complete Agreement; Amendments. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.
​
(i)Severability of Provisions. Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.
​
(j)Counterparts. This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment. Delivery of an executed counterpart of a signature page of this Amendment by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.
​
(k)Loan Documents. This Amendment and the documents related thereto shall constitute Loan Documents.
​
(l)Electronic Execution of Certain Other Documents. The words “execution,” “execute”, “signed,” “signature,” and words of like import in or related to any document to be signed in connection with this Amendment and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the California Uniform Electronic Transaction Act, or any other similar state laws based on the Uniform Electronic Transactions Act.
​
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
​
​

4

​

​
IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as of the date first above
written.
​
​
	​
	BORROWER:

	​
	​

	​
	CENTURY THERAPEUTICS, INC.

	​
	​

	​
	Signature:
	

	​
	​
	​

	​
	Print Name:
	Douglas Carr

	​
	​
	​

	​
	Title:
	CFO

​
​
​
​
​
[SIGNATURES CONTINUE ON THE NEXT PAGE]
​
​
​
​
​

[Signature Page to First Amendment to Loan and Security Agreement]

​

​
	​
	AGENT:

	​
	​

	​
	HERCULES CAPITAL, INC.

	​
	​

	​
	Signature:
	

	​
	​
	​

	​
	Print Name:
	Jennifer Choe

	​
	​
	​

	​
	Title:
	Associate General Counsel

​
​
	​
	LENDERS:

	​
	​

	​
	HERCULES CAPITAL, INC.

	​
	​

	​
	Signature:
	

	​
	​
	​

	​
	Print Name:
	Jennifer Choe

	​
	​
	​

	​
	Title:
	Associate General Counsel

​

[Signature Page to First Amendment to Loan and Security Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]